Shuhua Yi
Overview
Explore the profile of Shuhua Yi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
686
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Y, Yan Y, Shan D, Chen J, Liu W, Wang T, et al.
Cancer Biol Med
. 2025 Mar;
22(2).
PMID: 40072044
Objective: Our previous studies have indicated potentially higher proliferative activity of tumor cells in Chinese patients with mantle-cell lymphoma (MCL) than those in Western. Given the success and tolerability of...
2.
Yu Y, Li Y, Cui R, Yan Y, Li F, Chen Y, et al.
Signal Transduct Target Ther
. 2025 Mar;
10(1):85.
PMID: 40069155
Large granular lymphocytic leukemia (LGLL) is characterized by the clonal proliferation of cytotoxic T lymphocytes or NK cells. Standard first-line immunosuppressive treatments have limitations, achieving complete remission (CR) rates of...
3.
Li Y, Cui R, Yu Y, Huang Y, Yan Y, Sun J, et al.
Oncologist
. 2025 Mar;
30(3).
PMID: 40063609
NK-large granular lymphocytic leukemia (NK-LGLL) is a rare chronic lymphoproliferative disorder and displays heterogeneity that remains insufficiently defined. CD56 plays a pivotal role in NK-cell maturation linked to cytotoxicity. However,...
4.
Xiong W, Yan Y, Wang T, Sui W, Yu Y, Yu T, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40053705
Purpose: Waldenström macroglobulinemia (WM) is a rare type of lymphoma, with no optimal treatment. BTK inhibitor have shown promising outcomes, yet achieving deep remission (VGPR or CR) remains challenging and...
5.
Liu Y, Lin N, Yi S, Huang H, Guo Y, Zhang Q, et al.
Int J Cancer
. 2025 Feb;
PMID: 40018797
Pirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi), demonstrated clinically meaningful antitumor responses in covalent BTKi pretreated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or...
6.
Yan Y, Huang Y, Yu Y, Duan Z, Li Y, Lyu R, et al.
Ann Hematol
. 2025 Feb;
PMID: 39998672
Recent advances in measurable residual disease (MRD) technology have significantly enhanced predictive accuracy for outcomes in various hematologic malignancies, serving as a crucial surrogate endpoint. However, in mantle cell lymphoma...
7.
Zha J, Chen Q, Zhang W, Jing H, Ye J, Liu H, et al.
Biomark Res
. 2025 Jan;
13(1):2.
PMID: 39754201
Background: Disease progression within 24 months (POD24) significantly impacts overall survival (OS) in patients with follicular lymphoma (FL). This study aimed to develop a robust predictive model, FLIPI-C, using a...
8.
Cui R, Yu Y, Li Y, Huang Y, Sun J, Yan Y, et al.
Br J Haematol
. 2024 Oct;
205(6):2506-2509.
PMID: 39419490
No abstract available.
9.
Yan Y, Yu Y, Xiong W, Wang J, Yao Y, Jia Y, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5483-5493.
PMID: 39373694
Purpose: This study aims to explore the incidence and clinical features of MYD88 and CXCR4 mutations in patients with Waldenström macroglobulinemia (WM) and determine the optimal method for routine clinical...
10.
Song B, Wang D, Yan X, Yan P, Liu H, Li H, et al.
BMC Womens Health
. 2024 Aug;
24(1):455.
PMID: 39138442
Background: Appropriate physical activity (PA) and good sleep are beneficial to maternal and fetal health. This paper sought to explore the associations of PA and sleep quality among healthy women...